Expertise in
9
conditions

Dr. Christopher Sweeney

Oncology
Dana-Farber Cancer Institute
450 Brookline Ave, 
Boston, MA 
Expertise in
9
conditions
Dana-Farber Cancer Institute
450 Brookline Ave, 
Boston, MA 

Overview

Christopher Sweeney is an Oncologist in Boston, Massachusetts. Dr. Sweeney is highly rated in 9 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Testicular Cancer, Orchiectomy, and Prostatectomy.

His clinical research consists of co-authoring 323 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in MA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Dana-Farber Cancer Institute
450 Brookline Ave, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug
Study Drugs: Enzalutamide, Non-Steroidal Anti Androgen, Luteinizing Hormone Releasing Hormone Analog or Surgical Castration
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Drug, Procedure
Study Drugs: Paclitaxel, Ifosfamide, Cisplatin, Pegylated G-CSF, G-CSF, Carboplatin, Etoposide Phosphate
Study Phase: Phase 3
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2023
Intervention Type: Radiation, Drug
Study Drugs: Darolutamide, Luteinizing Hormone-Releasing Hormone Analog
Study Phase: Phase 3
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

322 Total Publications

Downregulation of ANPEP Is Associated with Aggressive Prostate Cancer and Poor Disease-specific Outcomes.
Downregulation of ANPEP Is Associated with Aggressive Prostate Cancer and Poor Disease-specific Outcomes.
Journal: European urology open science
Published: December 12, 2025
Similar Doctors
Expertise in
21
conditions
Dr. Matthew Davids
Oncology
Expertise in
21
conditions
Dr. Matthew Davids
Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Davids is an Oncologist in Boston, Massachusetts. Dr. Davids is highly rated in 21 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Tissue Biopsy, and Bone Marrow Transplant.

Expertise in
44
conditions
Dr. Eric Jacobsen
Oncology
Expertise in
44
conditions
Dr. Eric Jacobsen
Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eric Jacobsen is an Oncologist in Boston, Massachusetts. Dr. Jacobsen is highly rated in 44 conditions, according to our data. His top areas of expertise are Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
21
conditions
Dr. Toni Choueiri
Oncology
Expertise in
21
conditions
Dr. Toni Choueiri
Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Toni Choueiri is an Oncologist in Boston, Massachusetts. Dr. Choueiri is highly rated in 21 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Urothelial Cancer, Nephrectomy, and Orchiectomy.

Frequently Asked Questions about Dr. Christopher Sweeney

How do I make an appointment with Dr. Christopher Sweeney?

You can book an appointment with Dr. Christopher Sweeney by calling their office at 617-632-3466. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Christopher Sweeney a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Christopher Sweeney is classified as an Elite expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Christopher Sweeney specialize in?

While Dr. Christopher Sweeney is a Oncology, they have specific expertise in Prostate Cancer, Orchiectomy, and Familial Prostate Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Christopher Sweeney participate in research or clinical trials?

Yes. Dr. Christopher Sweeney has published 322 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Christopher Sweeney's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sweeney's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile